See more : Aclara Resources Inc. (ARA.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Alector, Inc. (ALEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alector, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ichiken Co., Ltd. (1847.T) Income Statement Analysis – Financial Results
- Ngern Tid Lor Public Company Limited (TIDLOR.BK) Income Statement Analysis – Financial Results
- Richmond Vanadium Technology Limited (RVT.AX) Income Statement Analysis – Financial Results
- Natuzzi S.p.A. (NTZ) Income Statement Analysis – Financial Results
- Lakeside Holding Limited (LSH) Income Statement Analysis – Financial Results
Alector, Inc. (ALEC)
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 97.06M | 133.62M | 207.09M | 21.10M | 21.22M | 27.68M | 3.74M | 416.00K |
| Cost of Revenue | 192.12M | 8.47M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| Gross Profit | -95.05M | 125.15M | 17.68M | -135.77M | -79.31M | -45.35M | -26.18M | -13.26M |
| Gross Profit Ratio | -97.93% | 93.66% | 8.54% | -643.53% | -373.76% | -163.87% | -700.83% | -3,187.02% |
| Research & Development | 192.12M | 210.42M | 189.41M | 156.87M | 100.53M | 73.03M | 29.91M | 13.67M |
| General & Administrative | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.69M | 61.03M | 55.04M | 59.40M | 35.10M | 11.93M | 6.50M | 1.87M |
| Other Expenses | 0.00 | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Operating Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Cost & Expenses | 248.80M | 271.45M | 244.45M | 216.27M | 135.62M | 84.97M | 36.41M | 15.55M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.85M | 8.47M | 8.31M | 7.27M | 5.57M | 1.02M | 680.00K | 201.00K |
| EBITDA | -142.89M | -129.36M | -29.05M | -187.91M | -109.47M | -56.27M | -32.00M | -14.93M |
| EBITDA Ratio | -147.22% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -856.73% | -3,589.18% |
| Operating Income | -151.74M | -137.83M | -37.36M | -195.17M | -114.40M | -57.29M | -32.68M | -15.13M |
| Operating Income Ratio | -156.33% | -103.16% | -18.04% | -925.08% | -539.16% | -206.99% | -874.94% | -3,637.50% |
| Total Other Income/Expenses | 26.56M | 7.78M | 1.03M | 4.95M | 9.02M | 5.04M | 199.00K | 22.00K |
| Income Before Tax | -125.18M | -130.06M | -36.33M | -190.23M | -105.39M | -52.25M | -32.48M | -15.11M |
| Income Before Tax Ratio | -128.97% | -97.33% | -17.54% | -901.64% | -496.65% | -188.78% | -869.61% | -3,632.21% |
| Income Tax Expense | 5.21M | 3.25M | -8.32M | -7.27M | -5.57M | 5.04M | 0.00 | 0.00 |
| Net Income | -130.39M | -133.31M | -28.01M | -182.96M | -99.81M | -52.25M | -32.48M | -15.11M |
| Net Income Ratio | -134.34% | -99.77% | -13.53% | -867.21% | -470.39% | -188.78% | -869.61% | -3,632.21% |
| EPS | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| EPS Diluted | -1.56 | -1.62 | -0.35 | -2.35 | -1.62 | -0.76 | -0.63 | -0.29 |
| Weighted Avg Shares Out | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
| Weighted Avg Shares Out (Dil) | 83.73M | 82.47M | 80.42M | 77.76M | 61.73M | 68.37M | 51.22M | 51.22M |
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
Alector to Host Mid-Year Earnings Conference Call
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Alector to Participate in Upcoming Healthcare Conferences
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector to Participate in Upcoming Healthcare Conferences
Source: https://incomestatements.info
Category: Stock Reports